Are GLP-1s safe to take long-term?

The evidence base here is unusually deep for a “new” drug class, because GLP-1s aren’t actually new — exenatide arrived in 2005 and liraglutide in 2010, initially for diabetes. Millions of patient-years of use later, the long-term picture looks like this: Reassuring: - SELECT (17,000+ participants, ≈3+ years): semaglutide reduced major cardiovascular events by 20% — long-term benefit, not just absence of harm. - Multi-year diabetes outcome trials (LEADER, SUSTAIN-6, SURPASS) showed no accumulating organ toxicity; kidney outcomes have trended favorable (FLOW trial). - Two-year obesity trials (STEP 5, SURMOUNT-4) showed side effects concentrate early and decline with time on drug. The watch-list: - Pancreatitis and gallbladder disease: uncommon (roughly 1–3% range for gallbladder events, less for pancreatitis) but real; rapid weight loss itself contributes to gallstones. - Thyroid C-cell tumors: seen in rodents, never confirmed in humans — but it drives a boxed warning and absolute contraindications. - Muscle loss with prolonged use if protein and resistance training are neglected (details). - Compounded and sublingual forms carry the additional caveat that the specific formulations lack long-term study — the molecule’s record is borrowed, not earned. The fair framing: for people who meet criteria, the best long-term data we have suggests staying on a GLP-1 is safer than the untreated obesity it replaces. That calculus is individual — which is what your clinician conversation is for.